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Background: Use of methadone for the treatment of opioid addiction is an effective harm-reduction approach,
although variability in treatment outcomes among individuals has been reported. Men and women with opioid
addiction have been known to differ in factors such as opioid use patterns and characteristics at treatment entry;
however, little has been reported about differences in methadone treatment outcomes between men and women.
Therefore, we present a protocol for a systematic review which aims to provide a summary of existing literature on
sex differences in outcomes of methadone treatment for opioid addiction.
Methods/Design: Electronic search of PubMed/MEDLINE, EMBASE, PsycINFO, and CINAHL databases will be
conducted using a priori defined search strategy. Two authors (MB and BBD) will independently screen potential
articles for eligibility using pre-determined inclusion and exclusion criteria and extract key information using a data
extraction form designed for this study. Discrepancies will be resolved using a third party (ZS). The primary outcome
will be sex differences in response to treatment defined as abstinence from illicit opioid use. We will also assess sex
differences in treatment outcomes including treatment retention, remission status post-treatment, polysubstance
abuse, methadone dose, drug-related adverse events, health status, psychological status, mortality, criminal activity,
high risk sexual behavior, social support/relations, and employment. A meta-analysis will be conducted if possible;
risk of bias and overall quality of evidence will be assessed to determine confidence in the estimates.
Discussion: We anticipate that this review will highlight how men and women differ in methadone treatment
outcomes and allow us to generate conclusions that can be applied to treatment in a clinical setting.
Systematic review registration: PROSPERO CRD42013006549
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ProtocolBackground
The use of illicit opioids continues to pose a problem
both at the individual and societal levels, even more so
with the exponentially increasing rates of prescription
opioid use in North America [1-3], increasing the risk of
development of opioid addiction. Infection [4], medical
and psychiatric comorbidity [5], polysubstance use [5],* Correspondence: samaanz@mcmaster.ca
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unless otherwise stated.and criminal behavior [6] are among a few of the risks
associated with opioid addiction, in addition to a rise in
opioid-related deaths [2].
Methadone maintenance treatment (MMT) is the most
widely used harm-reduction approach to treating opioid
addiction [7]. Methadone is a synthetic analgesic with the
ability to inhibit the euphoric effects of opioids and
provide relief of withdrawal symptoms due to its longer
duration of action [8]. MMT began to receive attention
shortly after its development in the early 1940s, which led
to the opening of methadone clinics across the world, and
later in North America [9]. Since then, the number of
patients entering treatment has grown about fivefold [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients in Ontario, Canada, alone [11], which represents
approximately 25% of Ontario’s illicit opioid user popula-
tion [10]. Although progress has been made with MMT, it
is evident that it is still not widely used in opioid addiction
populations on the larger scale.
Despite the documented effectiveness of methadone as
a substitute opioid therapy, methadone has also been
reported to produce a large inter-individual variability in
response [12], adding an additional layer of complexity
to treatment strategies. Traditionally, the population of
individuals suffering from opioid addiction has been pri-
marily men, with most studies at the time focusing on
opioid-dependent men [13,14]. In the most recent 30 years,
there has been an increase in the number of women with
opioid addiction [15], which calls for a re-examination of
literature on sex differences in opioid addiction in general,
and response to MMT specifically.
Sex differences in opioid addiction [10,16-18] and
methadone treatment [16,19-22] have been reported;
significant sex differences in age, ethnicity, marital status,
education, and employment [23], as well as patterns of
drug use [21], treatment entry [24], and social support
[25] have been identified. Women are typically younger,
married, unemployed, and have an earlier onset age of
heroin use [23]. Men often use opioids for recreational
purposes [16] and have a slower disease progression than
women [24]. Additionally, men report earlier treatment
entry, more frequent utilization of substance abuse treat-
ment, and fewer psychological and medical problems
at treatment admission compared to women [17]. It is
becoming clear that treatment needs for men and
women are not the same, which points to a demand
for separate treatment strategies. The available studies
on opioid addiction in the literature are often limited
to men [26] or specific ethnic groups, focus on clinical
profiles prior to or at treatment entry [16,19-22], or inves-
tigate methadone dose as a single outcome of treatment in
association with other factors [27-30]. Sex differences have
also been examined in opioid addiction patients treated
with methadone in association with factors including
prescription opioid use [31], drug use patterns [20], drug
treatment utilization [32], psychiatric comorbidity [5,33],
smoking outcomes [34], and quality of life [35]; however,
little has been reported about differences in methadone
treatment outcomes between men and women. Few stud-
ies have investigated methadone treatment retention,
response, remission, adverse events, health status, social
relations, criminal activity, and mortality with a specific
focus on sex difference, providing inconsistent results and
leaving a large gap in the literature with regards to sex
differences in response to MMT.
It is also evident that men and women vary in multiple
aspects of addiction characteristics and should thereforebe provided sex-specific treatment. Implementation of
separate treatment approaches for men and women may
prove to be a more efficient way to manage this disorder
and eventually improve patient-related health outcomes.
This review aims to determine whether or not men and
women differ in methadone treatment outcomes.
Objectives
The objective of this review is to summarize the current
status of literature regarding sex differences in metha-
done treatment outcomes by systematically reporting the
available research to date. Specifically, we aim to:
1. Assess how men and women differ in methadone
outcomes related to drug-use behavior,
health status, and sociobehavioral functioning.
2. When suitable, combine the statistical outcomes
in a summary estimate through meta-analytical
approaches.
3. Critically appraise the literature and determine
areas that require further investigation.
Methods/Design
Inclusion and exclusion criteria
This systematic review will include completed random-
ized controlled trials (RCTs) and observational studies of
methadone treatment outcomes in men and women.
Included studies will focus primarily on sex differences,
as opposed to studies on separate populations of men or
women. Included studies must also have been conducted
in the context of methadone treatment for opioid addic-
tion. Studies including patients that are undergoing a
substitute opioid therapy other than methadone (that is,
buprenorphine/naloxone, naltrexone) or using methadone
for the purpose of detoxification (not maintenance) will
be excluded. Studies investigating patient subpopulations
such as pregnant women or incarcerated individuals will
be excluded as they are too specific to represent the over-
all population of opioid-dependent individuals and may
not allow for the application and generalizability of our
findings to community samples. Sex differences in these
populations may also be influenced by their environment,
leading to a high potential for confounding and bias in the
outcomes studied. Patients that are using methadone for
the treatment of a condition other than opioid addiction
(that is, chronic pain) will also be excluded. Participants
shall include both men and women who are receiving
methadone treatment for a diagnosis of opioid depend-
ence. No other limitations will be applied (including age
or ethnicity) as our intent is to retrieve all articles on sex
differences in methadone treatment without restrictions
based on population characteristics. The primary outcome
of this review will be the presence of sex differences
in methadone treatment response, defined as abstinence
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and/or urinalysis. Sex differences in treatment outcomes
will also be assessed with respect to three life domains: drug
use-related behavior, health status, and sociobehavioral
functioning. These outcomes include treatment retention/
duration, remission status post-treatment, polysubstance
abuse, methadone dose, drug-related adverse events, health
status, psychological status, mortality, criminal activity, high
risk sexual behavior, social support/relations, and employ-
ment. A complete list of how these outcomes are described,
defined, and measured in the literature is available in
Table 1.
Search strategy
We shall identify all studies relevant to this review with
no language or time restraints. We will search the
PubMed/MEDLINE, EMBASE, PsycINFO, and CINAHL
databases for relevant articles. Relevant search terms
and their medical subject heading (MeSH) equivalents
will be used in varying combinations; refer to Table 2 for
the complete search strategy. In order to maximize the
number of relevant articles retrieved, treatment outcomes
will not be included in the search. We will use a wide
search to include titles, abstracts, and keyword fields to
avoid missing important articles whose title may not
reflect the content of the article. Articles will be excluded
by limiting the search to humans. We will also manually
review reference lists of included studies for studies that
may have been missed in the initial search. Grey literature
will not be reviewed as we are looking for complete
published data only.
Data screening
Two independent raters (MB and BBD) will screen all
citations and abstracts retrieved using the search strategy
and identify all eligible articles. Articles that meet the pre-
determined criteria will be included for full-text review.
Disagreements at any phase of the review process will be
resolved by discussion or, in the case where a consensus is
not reached, a third independent rater (ZS) will determine
eligibility. Ineligible studies will be excluded from the
review and reasons for exclusion will be recorded. Inter-
rater agreement will be calculated using the Kappa
statistic [48] for each phase of screening. Authors will
be contacted directly if further data clarification is needed.
Data extraction
The two authors (MB and BBD) will independently
extract data from the studies using a pre-established
pilot-tested data extraction form (see Additional file 1).
Information obtained will include the author and year of
publication, city and country of publication, title of article,
journal name, study design, and description of sample
population, including total number of men and womenstudy participants, mean age (total and men versus women),
and ethnicity. Primary and secondary outcomes, outcome
measures, statistical analyses, results, and conclusions will
also be recorded. In the case of missing or incomplete
data, authors will be contacted for further details. Data
will be combined to produce a summary estimate in a
meta-analysis if the extracted data allows it.
Assessment of quality
Two authors (MB and BBD) will independently assess
the risk of bias of included studies using the Newcastle-
Ottawa Scale (NOS) [49] for observational studies and
the Cochrane Collaboration’s tool [50] for assessing risk
of bias in RCTs. For observational studies, two authors
(MB and BBD) will independently assess the risk of bias
of each included study using an adapted version of a
modified NOS, specific to the context of this review.
This will include seven questions spread across four
domains of evaluation; methods for selecting study partici-
pants (selection bias), methods to control for confounding
(performance bias), statistical methods (detection bias),
and methods for measuring exposure and outcome vari-
ables (information bias). Risk of bias is measured on a
scale of 0 (high risk of bias) to 3 (low risk of bias) and a
specific description with examples of both high and low
bias is provided. Items regarding selection of participants
(representativeness of sample) and ascertainment of out-
come (objective versus subjective measures) were retained,
while other items relating to the comparability of groups
and adequate follow-up for cohort and case-control stud-
ies were removed as these were not directly applicable to
our topic of interest. We also introduced categories that
emphasize statistical methods, confounding effects, and
reporting of data to ensure that bias in methodology is
assessed. These scales will be used to measure the risk of
bias on a per study basis or categorized by domain to
develop a general conclusion about the sources of bias in
the studies included in this review (see Additional file 2).
Cochrane’s tool for assessing risk of bias in RCTs includes
seven domains; random sequence generation, alloca-
tion concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome
data, selective reporting, and other bias. Each of these
domains will be evaluated according to high or low
risk of bias and will also be assessed on a per study
or per domain basis. If a meta-analysis is possible, we
will use the Grading of Recommendations, Assessment,
Development, and Evaluation framework to rate the
quality of evidence through investigation of risk of bias,
imprecision (random error), inconsistency, indirectness,
and publication bias. We will then summarize the evidence
for individual outcomes in summary of findings tables,
which will allow for assessment of our confidence in
the estimates.
Table 1 Definition of methadone treatment outcomes for assessment
Outcome Definition Measurement of variable Statistics Studies
Drug use-related behavior
Response to treatment Abstaining from illicit opioid use
throughout treatment duration
Urine screening Percentage [36-39]
Self reported opioid use (daily or






Proportion of participants completing
treatment; days in treatment from first
to last day of therapy





Proportion of patients retained in





Abstinence from use of illicit opioids
at follow-up
Urine screening t-test [37,39-41]
Self-reported opioid use (any) after
treatment
2x2 factorial ANOVA
Polysubstance use Use of at least two (non-opioid)
substances throughout the course
of treatment
Self-reported use of substances
daily or weekly or in last 30 days
Percentage [37,38]
Fischer’s Exact Test
Net reduction in proportion of
drug abuse after specific duration
Health and methadone-related outcomes
Methadone dose Average daily methadone dose Milligrams/day Difference in means (SD) [38]
Mean methadone dose after
specific duration in treatment
Drug-related adverse
events
Reaction to treatment drug Interview/physical examination Percentage [17]
Number of hospitalizations t-test
Health status Change in health status during
course of therapy
Interview/physical examination ANOVA [17,40]
Number of hospitalizations
Psychological status Comorbidity of psychiatric disorders Self-reported psychiatric problems Percentage [17,42-44]
Number of reported symptoms Relative risk
Validated psychiatric assessments ANOVA
Chi-square
Mortality Treatment-related death or illicit
drug use mortality





Annual death rate per year of age
Sociobehavioral functioning
Criminal behavior Involvement in illegal activities, arrests,
or incarcerations throughout treatment
or at follow-up
Interview/self-report Percentage [17,37,39]




Involvement in behaviors that put the
patient at high risk for HIV and other
infections





Number of sex partners Repeated measures ANOVA
Incidence of unprotected sex
Social relations/support Patient’s relationship status and
conception of his/her relationship
with others
Self-report ANOVA [17]
Number of close friends/family
Marital and family status
Ratings of interactions
Employment Status of employment and evidence
of financial income
Change in self-reported employment
status during treatment
Percentage [17,37,39,40]
Difference in means (SD)
Employment status after treatment
ANOVA, analysis of variance.
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Table 2 Search strategy for retrieval of relevant articles
from multiple databases
Database Search strategy
MEDLINE n = 401 1. Opioid-related disorders/dt, rh, th
[Drug Therapy, Rehabilitation, Therapy]










12. 1 or 2 or 3
13. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
14. 12 and 13
15. limit 14 to humans
EMBASE n = 180 1. Opioid-related disorders/dt, rh, th
[Drug Therapy, Rehabilitation, Therapy]










12. 1 or 2 or 3
13. 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
14. 12 and 13
15. limit 14 to humans
PsycINFO n = 241 1. exp Methadone Maintenance/ or
exp Methadone/






8. 2 or 3 or 4 or 5 or 6 or 7
9. 1 and 8
10. limit 9 to humans
Table 2 Search strategy for retrieval of relevant articles
from multiple databases (Continued)
CINAHL n = 23 1. Opioid abuse (TX All Text)
2. Methadone (TX All Text)
3. Methadone treatment programs
(MJ Word in Major Subject Heading)
4. Gender differences (TX All Text)
5. Sex differences
6. 1 or 2 or 3 and 4 or 5
7. limit 6 to human
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The results of this systematic review will be reported in
a narrative and informative manner; we will discuss
issues of study design and statistical analysis methods of
the included studies to determine which studies are
most informative and reliable. Where possible, we will
assess the studies in a combined statistical manner using
meta-analysis. The Kappa statistic will be used to meas-
ure level of agreement between independent raters. For
dichotomous outcomes, we will compute pooled odds
ratios using the Mantel-Haenszel random effects model,
in which the model is able to estimate between study vari-
ation through an evaluation of each study’s final results
and a Mantel-Haenszel fixed effect meta-analysis result.
For the summary estimates, we will employ a random
effects model, which assumes variation between studies
and their respective effect sizes. The nature of observa-
tional studies in this population is highly variable, there-
fore heterogeneity will be accounted for and will allow
us to develop aggregate estimates. We will assess the
participants, methods, and results of included studies for
heterogeneity, which will allow us to determine whether
results can be compared across studies. Possible sources
of heterogeneity include age groups, study design,
methodology, and definition of outcome. In case of
heterogeneity, subgroup analyses according to these
different categories will be performed. Included studies
will be presented in the form of a forest plot. We will use
Review Manager 5.1 software (The Cochrane Collaboration,
London, UK) for all statistical analysis and results will be
presented using 95% confidence intervals.
Presenting and reporting of results
We will report the systematic review according to the
Preferred Reporting Items for Systematic reviews and
Meta-Analyses guidelines [51]. A flow diagram will be
used to summarize the selection process of studies at
each phase and summary tables will be used to report
study characteristics and presence of sex differences per
methadone outcome. Publication bias will also be exam-
ined and assessed using Egger’s plot.
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Using evidence from this systematic review, we expect
to draw conclusions regarding the presence of sex differ-
ences in outcomes of MMT for opioid addiction. This
review will not only provide us with summary evidence
for which we can objectively make inferences about the
current status of literature, it will also allow us to critically
evaluate the methodological quality and risk of bias
present in the available evidence. The literature on metha-
done treatment focuses primarily on men and little is
known about women or how the sexes compare. We
anticipate that this review will highlight how men and
women differ in methadone treatment outcomes and
allow us to generate conclusions that can be applied to
treatment in a clinical setting. We will encourage health-
care professionals to make use of this information and
approach men and women dealing with opioid addiction
using different treatment strategies, catered to each sex
specifically. We are hopeful that this review will ultimately
establish the need for further examination into sex differ-
ences in methadone treatment in an effort to improve
treatment prognosis for individuals dealing with this
complex disorder.
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form contains the information which we intend to extract from included
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